MannKind Corporation announced that it recently presented initial data from a meal challenge that was part of the Phase 4 INHALE-3 trial of Afrezza insulin DPI plus basal insulin injections versus standard of care in Type 1 diabetics. Afrezza was approved by the FDA for the treatment of Type 1 and Type 2 diabetes in adults in 2014. The company said that it will … [Read more...] about MannKind presents data from Phase 4 trial of Afrezza inhaled insulin
News
Vast announces appointments in preparation for clinical development of ALX1 inhalation solution
Vast Therapeutics has announced the appointments of former Aradigm Senior Medical Director Paul Bruinenberg as Chief Medical Officer and Chris Polage as Medical Director in preparation for clinical development of its ALX1 inhalation solution. Bruinenberg was most recently Senior Medical Officer of the TB Alliance. In addition to his stint at Aradigm, Bruinenberg's … [Read more...] about Vast announces appointments in preparation for clinical development of ALX1 inhalation solution
Boehringer Ingelheim says it will limit out-of-pocket cost of its inhalers for some US patients
Boehringer Ingelheim said that "eligible patients" will pay no more than $35 per month for BI inhalers, including Atrovent HFA ipratropium MDI, Combivent Respimat ipratropium / albuterol SMI, Spiriva HandiHaler tiotropium DPI, Spiriva Respimat tiotropium SMI, Stiolto Respimat tiotropium / olodaterol SMI, and Striverdi Respimat olodaterol SMI. According to the company, … [Read more...] about Boehringer Ingelheim says it will limit out-of-pocket cost of its inhalers for some US patients
UWA researchers get A$500,000 grant for development of Spritz-OM probiotic nasal spray for ear infections
Researchers at the University of Western Australia have received a A$500,000 grant from the CUREator biotech incubator for development of the Spritz-OM probiotic nasal spray for the prevention of ear infections in children. The grant was one of 5 awarded recently as part of an effort to fund projects aimed at minimizing antimicrobial resistance. According to the … [Read more...] about UWA researchers get A$500,000 grant for development of Spritz-OM probiotic nasal spray for ear infections
Iconovo gets Innowide grant to support marketing activities in South Korea
Dry powder inhaler specialist Iconovo announced that the company has received a SEK 680,000 grant from the EU's Innowwide program that will fund a market study as part of Iconovo's plans to expand into the South Korean market. According to the company, the goal would initially be to attract South Korean customers for Iconovo's CDMO business and eventually licensing or … [Read more...] about Iconovo gets Innowide grant to support marketing activities in South Korea
Nocion raises $62 million for Phase 2b study of taplucainium DPI for the treatment of chronic cough
Nocion Therapeutics has announced that it raised $62 million in a Series B funding led by Monograph Capital and Arkin Bio Capital. Proceeds will be used to support a Phase 2b trial of its taplucainium (NTX-1175) inhaled dry powder for the treatment of chronic cough, the company said. In January 2020, Pulmatrix said that it had signed a deal to evaluate the use of … [Read more...] about Nocion raises $62 million for Phase 2b study of taplucainium DPI for the treatment of chronic cough
ARS Pharmaceuticals says Phase 2 trial of Neffy epinephrine nasal spray for urticaria met primary endpoints
ARS Pharmaceuticals announced that a Phase 2 trial of Neffy epinephrine nasal spray in patients with chronic spontaneous urticaria demonstrated that 1 mg and 2 mg doses of the intranasal epinephrine both produced statistically significant and clinically meaningful improvement in symptoms such as hives and itchy skin as soon as 5 minutes post dose. The inpatient study … [Read more...] about ARS Pharmaceuticals says Phase 2 trial of Neffy epinephrine nasal spray for urticaria met primary endpoints
Milestone says it will resubmit its NDA for etripamil nasal spray
Milestone Pharmaceuticals says that it held a Type A meeting with the FDA following receipt of a Refuse to File letter in December 2023 in response to the company's NDA for etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT). According to Milestone, the agency did not request any additional clinical trials. The company says that … [Read more...] about Milestone says it will resubmit its NDA for etripamil nasal spray
ReCode Therapeutics initiates Phase 1 trial of RCT2100 inhaled mRNA therapy for CF
ReCode Therapeutics has announced the initiation of a Phase 1 safety and tolerability study of RCT2100 inhaled CFTR mRNA-based therapy, which the company is developing for cystic fibrosis patients who do not benefit from CFTR modulators. The study is expected to enroll 32 healthy adults and will evaluate a single dose of nebulized RCT2100 against placebo. According … [Read more...] about ReCode Therapeutics initiates Phase 1 trial of RCT2100 inhaled mRNA therapy for CF
The DDL New Researcher Network Expands its Activities
By Julia Berends, Cord Kühnl, and Lucy Goodacre The New Researcher Network (NRN) was founded as a sub-committee of the Drug Delivery to the Lungs (DDL) conference in 2019 to actively foster interaction and collaboration among early-career OINDP researchers and to build a robust community of emerging scholars. The first NRN lunch and evening session took place at … [Read more...] about The DDL New Researcher Network Expands its Activities